Sofituzumab vedotin

Drug Profile

Sofituzumab vedotin

Alternative Names: Anti-MUC16 ADC MMAE; Anti-MUC16 mAb MMAE; Anti-MUC16 MMAE ADC; Anti-MUC16 monoclonal antibody MMAE; Anti-MUC16 monoclonal antibody monomethyl auristatin E conjugate; Anti-MUC16 monoclonal antibody vedotin; DMUC-5754A; MMAE anti-MUC16 mAb; MMAE anti-MUC16 monoclonal antibody conjugate; Monomethyl auristatin E anti-MUC16 monoclonal antibody conjugate; RG-7458; Vedotin anti-MUC16 monoclonal antibody

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Genentech
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Fallopian tube cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer

Most Recent Events

  • 28 Jan 2015 Discontinued - Phase-I for Fallopian tube cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 28 Jan 2015 Discontinued - Phase-I for Ovarian cancer (Late-stage disease, Second-line therapy or greater) in USA (IV)
  • 28 Jan 2015 Discontinued - Phase-I for Pancreatic cancer (Inoperable/Unresectable) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top